Somewhat Positive News Coverage Somewhat Unlikely to Affect Antares Pharma (ATRS) Stock Price
Media stories about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Antares Pharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.6572528680392 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Shares of Antares Pharma, Inc. (ATRS) are worth at $3.21 – Wall Street Morning (wallstreetmorning.com)
- Antares Pharma, Inc. (ATRS) noted a price change of 0.31% and SciClone Pharmaceuticals, Inc. (SCLN) closes with a … – Stocks Gallery (stocksgallery.com)
- Antares Pharma Inc (ATRS) and Lockheed Martin Corp (LMT) Shares Needle Moving On Volume – FLBC News (flbcnews.com)
- $13.79 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter (americanbankingnews.com)
- Antares Pharma Inc (ATRS) Reaches Active Mover List – Evergreen Caller (evergreencaller.com)
A number of equities research analysts have commented on the stock. Chardan Capital assumed coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target for the company. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 price target for the company in a report on Tuesday, July 18th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Finally, Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $4.34.
Antares Pharma (ATRS) traded down 3.82% on Thursday, hitting $3.02. 1,895,688 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $3.11 and a 200-day moving average price of $2.83. The stock’s market cap is $472.35 million. Antares Pharma has a 52-week low of $1.16 and a 52-week high of $3.37.
Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million for the quarter, compared to the consensus estimate of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Analysts predict that Antares Pharma will post ($0.11) earnings per share for the current fiscal year.
In other news, insider Fred M. Powell acquired 130,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The shares were bought at an average cost of $2.79 per share, with a total value of $362,700.00. Following the transaction, the insider now owns 331,434 shares of the company’s stock, valued at approximately $924,700.86. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.60% of the stock is owned by corporate insiders.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.